Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) Using Non-Myeloablative Conditioning with Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) Confirm a Low Incidence of Graft Versus Host Disease (GVHD) with Retained Anti-Tumor Activity

Holbrook Kohrt, MD, Brit Turnbull, PhD, G. Laport, MD, D. Miklos, MD, PhD, J. Shizuru, MD, PhD, L. Johnston, MD, S. Arai, MD, W. K. Weng, MD, PhD, J. Benjamin, MD, PhD, K. Blume, MD, R. Negrin, MD, P. Lavori, PhD, S. Strober, MD, R. Lowsky, MD

Blood (2008) 112 (11): 3310.

https://doi.org/10.1182/blood.V112.11.3310.3310

Published: 2008

Journal Articles

Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) after Non-Myeloablative Conditioning in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL).

Andrew R. Rezvani, MD, L. Norasetthada, MD, T. Gooley, PhD, Mohamed Sorror, MD, Stephen J. Forman, MD, Edward Agura, MD, T. Chauncey, MD, PhD, Richard T. Maziarz, MD, Michael Maris, MD, J. Shizuru, MD, PhD, B. Bruno, MD, James C. Wade, MD, T. Lange, MD, Andrew Yeager, MD, Brenda M. Sandmaier, MD, Rainer F. Storb, MD, David G. Maloney, MD, PhD

Blood (2007) 110 (11): 3037.

https://doi.org/10.1182/blood.V110.11.3037.3037

Published: 2007

Journal Articles

Allogeneic Hematopoietic Cell Transplantation (HCT) with Nonmyeloablative Conditioning after Failed Myeloablative HCT: Factors Affecting Outcomes.

Frederic Baron, R. Storb, B. Storer, D. Maloney, M. Maris, D. Niederwieser, J. Shizuru, T. Chauncey, B. Bruno, S. Forman, P. McSweeney, R. Maziarz, M. Pulsipher, E. Agura, M. Sorror, J. Wade, B. Sandmaier

Blood (2005) 106 (11): 1143.

https://doi.org/10.1182/blood.V106.11.1143.1143

Published: 2005

Journal Articles

Haploidentical Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) Conditioning Protects Against Acute Graft Versus Host Disease (GVHD).

R. Lowsky, K. Heydari, B. Sahaf, J. Shizuru, G. Laport, L. Johnston, K. Stockerl-Goldstein, S. Arai, D. Miklos, K. Blume, L. Herzenberg, R. Negrin, S. Strober

Blood (2005) 106 (11): 2904.

https://doi.org/10.1182/blood.V106.11.2904.2904

Published: 2005

Journal Articles

HLA-Matched Related (MRD) or Unrelated Donor (URD) Non-Myeloablative Hematopoietic Cell Transplantation (HCT) for Patients (pts) with Refractory and Relapsed Aggressive Non Hodgkin Lymphoma (NHL).

L. Norasetthada, M. B. Maris, B. M. Sandmaier, T. Gooley, S. Forman, E. Agura, R. T. Maziarz, J. Shizuru, D. Niederwieser, R. Storb, D. G. Maloney

Blood (2004) 104 (11): 2307.

https://doi.org/10.1182/blood.V104.11.2307.2307

Published: 2004

Journal Articles

Unrelated Donor Peripheral Blood Stem Cell (PBSC) Transplantation Using Nonmyeloablative Conditioning and Mycophenolate Mofetil (MMF) TID Results in High Engraftment Rates.

Michael B. Maris, MD, B. M. Sandmaier, MD, B. Storer, PhD, J. Shizuru, MD, PhD, D. Maloney, MD, PhD, E. Agura, MD, PhD, D. Niederwieser, MD, M. Pulsipher, MD, R. T. Maziarz, MD, P. McSweeney, MD, J. Wade, MD, A. Langston, MD, T. Chauncey, MD, B. Bruno, MD, A. Woolfrey, MD, M.T. Little, PhD, K. Blume, MD, R. Storb, MD

Blood (2004) 104 (11): 1818.

https://doi.org/10.1182/blood.V104.11.1818.1818

Published: 2004

NARROW

Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) Using Non-Myeloablative Conditioning with Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) Confirm a Low Incidence of Graft Versus Host Disease (GVHD) with Retained Anti-Tumor Activity

Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) after Non-Myeloablative Conditioning in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL).

Allogeneic Hematopoietic Cell Transplantation (HCT) with Nonmyeloablative Conditioning after Failed Myeloablative HCT: Factors Affecting Outcomes.

Haploidentical Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) Conditioning Protects Against Acute Graft Versus Host Disease (GVHD).

HLA-Matched Related (MRD) or Unrelated Donor (URD) Non-Myeloablative Hematopoietic Cell Transplantation (HCT) for Patients (pts) with Refractory and Relapsed Aggressive Non Hodgkin Lymphoma (NHL).

Unrelated Donor Peripheral Blood Stem Cell (PBSC) Transplantation Using Nonmyeloablative Conditioning and Mycophenolate Mofetil (MMF) TID Results in High Engraftment Rates.

Email alerts

ASH Publications

American Society of Hematology

Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) Using Non-Myeloablative Conditioning with Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) Confirm a Low Incidence of Graft Versus Host Disease (GVHD) with Retained Anti-Tumor Activity

Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) after Non-Myeloablative Conditioning in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL).

Allogeneic Hematopoietic Cell Transplantation (HCT) with Nonmyeloablative Conditioning after Failed Myeloablative HCT: Factors Affecting Outcomes.

Haploidentical Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) Conditioning Protects Against Acute Graft Versus Host Disease (GVHD).

HLA-Matched Related (MRD) or Unrelated Donor (URD) Non-Myeloablative Hematopoietic Cell Transplantation (HCT) for Patients (pts) with Refractory and Relapsed Aggressive Non Hodgkin Lymphoma (NHL).

Unrelated Donor Peripheral Blood Stem Cell (PBSC) Transplantation Using Nonmyeloablative Conditioning and Mycophenolate Mofetil (MMF) TID Results in High Engraftment Rates.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only